APA (7th ed.) Citation

Yudai Fujiwara, Hidekatsu Kuroda, Tamami Abe, Keisuke Kakisaka, Ippeki Nakaya, Asami Ito, . . . Takayuki Matsumoto. (2024). Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment. Adis, Springer Healthcare.

Chicago Style (17th ed.) Citation

Yudai Fujiwara, et al. Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment. Adis, Springer Healthcare, 2024.

MLA (9th ed.) Citation

Yudai Fujiwara, et al. Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment. Adis, Springer Healthcare, 2024.